MAPK8 and soft tissue sarcoma: In approximately 10% of soft-tissue sarcomas, largely irrespective of histological subtype and possibly independent of JUN amplification status, JNK inhibitors that can replace the inhibitory function no longer provided by SERPINB3 may restore JNK activity to normal condition.